ADVERTISEMENT

Stocks Radar: Future Supply, Plastiblends, Dish TV

The BSE Sensex fell as much as 0.31 percent to 32,702.12, while the NSE Nifty 50 dropped 0.41 percent to 10,076.

An electronic ticker board indicates the closing figures of the S&P BSE Sensex at the Bombay Stock Exchange (BSE) building in Mumbai, India. (Photographer: Prashanth Vishwanathan/Bloomberg)
An electronic ticker board indicates the closing figures of the S&P BSE Sensex at the Bombay Stock Exchange (BSE) building in Mumbai, India. (Photographer: Prashanth Vishwanathan/Bloomberg)

Indian equity benchmarks started the session on a weak note, amid investors awaiting Reserve Bank of India’s stance on monitory policy to be announced later today.

The S&P BSE Sensex Index fell as much as 0.31 percent to 32,702.12, while the NSE Nifty 50 Index dropped as much as 0.41 percent to 10,076.

The market breadth was tilted in favour of the sellers. Thirteen of the 19 sector gauges compiled by the BSE Ltd. fell, led by the S&P BSE Power Index’s 1.25 percent decline. On the flip side, the S&P BSE Realty Index rose 0.47 percent, making it the best performer.

Nifty PSU Bank Index: Falls Ahead Of RBI’s Decision

The Nifty PSU bank index fell nearly 1 percent ahead of the monitory policy committee decision on interest rates.

A poll by Bloomberg News suggests that most economists expect a status quo policy. Forty-one of 46 economists polled expect the repo rate to remain unchanged at 6 percent, while a small minority expects another 25 basis point cut to 5.75 percent.

Stocks Radar: Future Supply, Plastiblends, Dish TV

Atlas Cycles: Banks Downgrade Debt To Non-Performing

Shares of the Sonepat-based bicycle manufacturer fell as much as 4.99 percent to Rs 207.65, extending a two-day decline.

All bank accounts of Atlas Cycles (Haryana) Ltd. with a branch of Bank of Baroda and Central Bank of India in Sonepat have slipped to the non-performing assets category, the company said in an exchange filing.

Trading volume was 25.9 times the 20-day average during early trading today.

Shilpa Medicare: Falls On FDA Observations

Shares of the pharma ingredients exporter fell as much as 6.54 percent to Rs 596.25

Shilpa Medicare Ltd. received a total of 10 observations from U.S. FDA for its Jadcherla Plant, three of which were on analyst specifications and methods.

Trading volume was 222 times the 20-day average during early trading today. The stock has given negative returns of 11.51 percent, compared to Sensex’s returns of 23.02 percent.

Plastiblends: Falls On Net Profit Plunge

Shares of the Mumbai-based specialty chemical company fell as much as 8.5 percent, the most since July 10, to Rs 220., extending a three-day decline.

Plastiblends India Ltd. ’s net profit for the second quarter of the current financial year fell 62.5 percent to Rs 3 crore.

Earnings Highlights:

  • Revenue up 12 percent at Rs 144 crore
  • Net profit down 62.5 percent at Rs 3 crore
  • Ebitda down 33 percent at Rs 10 crore
  • Margin at 6.9 percent versus 11.6 percent

The stock has given negative returns of 0.25 percent as compared to Sensex’s returns of 23.02 percent.

Dish TV: Records Loss In Q2

Shares of the Noida-based cable TV network fell as much as 2.92 percent to Rs 78.2.

Dish TV India Ltd. recorded a loss of Rs 16 crore compared to a year-ago's net profit of Rs 70 crore in the second quarter of the current financial year.

Earnings Highlights:

  • Revenue down 4 percent at Rs 749 crore
  • Net loss of Rs 16 crore from a profit of Rs 70 crore
  • Ebitda down 18 percent at Rs 216.5 crore
  • Margin at 28.9 percent versus 34 percent

The stock has given negative returns of 6.14 percent as compared to Sensex’s returns of 23.02 percent.

Glenmark: Falls On FDA Observations

Shares of the Mumbai-based pharmaceutical company fell as much as 0.87 percent to Rs 540 after it snapped a weak long losing streak yesterday.
Glenmark Pharmaceuticals Ltd. received seven observations along with Form 483.

Aurobindo Pharma: FDA NOD For Ranolazine

Shares of the Hyderabad based pharmaceutical firm fell as much as 0.48 percent to Rs 665.75.

Aurobindo Pharma Ltd. gets U.S. FDA nod for Ranolazine Extended Release Oral Tablet.

The company’s stock is 22 percent below the Bloomberg consensus target price and the analyst consensus rating is equivalent to buy.